Tessera Therapeutics
Tessera Therapeutics builds RNA-encoded gene-editing enzymes for in-vivo genetic disease correction.
The call
Tessera holds real gene-editing IP and Regeneron money but is racing rivals like Beam and Vertex who are already dosing patients or shipping approved cures.
Tessera Therapeutics develops a system to edit genes inside the body using special enzymes and a delivery method designed to avoid immune rejection. The company has partnerships with major organizations like Regeneron and the Gates Foundation, but has not yet gotten any treatment approved by regulators. Beam Therapeutics, a rival company, has already tested its gene-editing treatment in 29 patients for the same lung disease Tessera is targeting, and showed strong results, while Tessera's lead treatment is just starting human trials. Tessera recently laid off workers, lost its CEO to a competitor, and has not raised fresh funding since 2022, which makes it vulnerable. The one thing that could change the picture is if Tessera's first treatment shows surprisingly strong results in upcoming patient tests, or if the company can secure new money to fund operations through approval.
Why
01
AI pressure: None apparent. No AI lab or model is displacing Tessera's chemistry-and-biology work; the fight here is clinical data, not algorithms. Could AI do the core job? Unlikely.
02
Bigger players: Vertex Pharmaceuticals / CRISPR Therapeutics (Casgevy). Casgevy is already an approved sickle cell cure on the market while Tessera's own SCD program is still preclinical. Could a giant copy it? Probably.
03
What protects it. Its own patented non-viral Gene Writing platform and Regeneron's cash keep it funded and technically distinct from rivals.
What would change this call
TSRA-196 first-in-human dosing and early biomarker data release. Shows whether Tessera's platform can compete clinically with Beam in AATD.
Beam Therapeutics' AATD pivotal cohort data readout in H2 2026. A strong Beam result would widen Tessera's competitive gap in the same indication.
Whether Tessera closes a new priced funding round by end-2026 or mid-2027. Tests if investors still value the company at or above its stale $1.7B mark.
Beam Therapeutics' AATD pivotal cohort data readout in H2 2026. A strong Beam result would widen Tessera's competitive gap in the same indication.
Whether Tessera closes a new priced funding round by end-2026 or mid-2027. Tests if investors still value the company at or above its stale $1.7B mark.
Key numbers
- Regeneron paid $150M upfront, up to $125M more in milestones
- Tessera cut 90 employees in March 2026 layoff
- Beam dosed 29 AATD patients, ~80% protein reduction
Named risks
- Lead asset TSRA-196 enters clinic well behind Beam's dosed, pivotal-stage AATD program.
- Abrupt CEO change in July 2026 during a critical clinical inflection point.
- No priced equity round since April 2022 leaves $1.7B valuation stale and untested.
- 90-person layoff in March 2026 signals contraction alongside clinical ramp-up.
- Heavy reliance on a single near-term clinical asset (TSRA-196) for momentum.
Rivals, as read in July 2026
| Rival | Direction | Evidence |
|---|---|---|
| Beam Therapeutics | losing to | 29 AATD patients dosed with ~80% reduction, entering pivotal cohort H2 2026 (Jul 9, 2026) |
| Prime Medicine | contesting | Cleared IP fight, targeting Q3 2026 AATD filing, racing same indication as Tessera |
| CRISPR Therapeutics/Vertex | losing to | Casgevy already approved for sickle cell/thalassemia since December 2023 |
| Arbor Biotechnologies | contesting | Reported single-AAV in vivo brain editing breakthrough at ASGCT, May 12, 2026 |
Questions people ask
- Is Tessera Therapeutics profitable?
- No. Tessera is a private, clinical-stage biotech with no disclosed product revenue as of July 2026. Its cash comes from partnership and grant deals, including a $150M upfront payment from Regeneron announced December 1, 2025, and up to $50M from the Gates Foundation in December 2024.
- Who owns Tessera Therapeutics?
- Tessera was founded in 2018 by Flagship Pioneering, which continues to install its own executives as CEO. The company remains private with no new priced equity round since its $300M+ Series C on April 19, 2022, which set a valuation near $1.7B.
- Is Tessera Therapeutics laying off employees?
- Yes. FierceBiotech reported on January 8, 2026 that Tessera planned to cut 90 employees in March 2026, framed as a shift from platform-building to clinical execution as its lead drug TSRA-196 enters the clinic.
- Who is Tessera Therapeutics' biggest competitor?
- In alpha-1 antitrypsin deficiency, Beam Therapeutics is well ahead: as of July 9, 2026 Beam had dosed 29 patients with about 80% reduction in mutant protein and was moving to a pivotal cohort in H2 2026, while Tessera's TSRA-196 is only entering the clinic.
- Could AI replace what Tessera Therapeutics does?
- Unlikely. Tessera's value sits in proprietary Gene Writer enzymes, non-viral LNP delivery chemistry, wet-lab discovery, and regulatory execution for its lead asset TSRA-196, none of which are information-processing tasks AI models currently substitute for.
- Who is Tessera Therapeutics' new CEO?
- Joseph Romanelli, a former Merck executive, was appointed President and CEO on July 23, 2026, replacing Michael Severino, who departed to become CEO of Sarepta Therapeutics effective July 28, 2026.
Timeline
- 2026-07-28CEO Michael Severino departs Tessera to become CEO of Sarepta Therapeutics
- 2026-07-23Joseph Romanelli named Tessera President and CEO
- 2026-07-09Beam Therapeutics reports 29 AATD patients dosed; Prime Medicine clears IP fight to enter AATD
- 2026-05-14ASGCT data show 85% average allele-editing in NHP long-term HSCs for sickle cell program
- 2026-03-23Gates Foundation grants Tessera funding for in vivo HIV cure research
- 2026-03Planned 90-person layoff takes effect, shifting focus to clinical execution
- 2026-01-08FierceBiotech reports Tessera plans 90-employee layoff for March 2026
- 2025-12-01Regeneron and Tessera announce co-development deal for TSRA-196 in AATD
- 2024-12-18Gates Foundation invests up to $50M in Tessera's sickle cell gene-writing program
- 2022-04-19Tessera closes over $300M Series C, setting valuation near $1.7B
Revision history
29 July 2026
First assessed. Losing its protection. The text above is fixed as of this date and is not edited afterwards.
In the same band
Sources
- Flagship Pioneering's Scientists Invent a New Category of Genome Engineering Technology: Gene Writing (2023-11-30)
- Valuation, Funding Rounds & Stock Price (2026-03-22)
- Tessera Therapeutics Announces Over $300M Series C Financing (2022-04-19)
- Tessera Therapeutics Valuation (2026-07-19)
- Tessera Therapeutics Receives Investment to Develop Curative In Vivo Genetic Treatment for Sickle-Cell Disease (2024-12-18)
- Tessera Therapeutics Receives Grant to Advance In Vivo Gene Writing Approaches Towards a Potential HIV Cure (2026-03-23)
- Regeneron and Tessera Therapeutics to Jointly Develop TSRA-196 for AATD (2025-12-01)
- Tessera Therapeutics 2026 Company Profile (2026-07-19)
- Flagship-founded Tessera plans to lay off 90 employees in March (2026-01-08)
- Tessera Therapeutics Showcases New Preclinical Data at ASGCT 29th Annual Meeting (2026-05-14)
- Prime Editing Clears IP Fight, Sets Q3 Filing for First Liver-Targeted AATD Drug (2026-07-09)
- Gates Foundation to invest in Tessera SCD gene-editing treatment (2025-01-09)